Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing
|Abstract:||A compound represented by the formula I ##STR1## wherein X is independently both F or both Cl or one X is independently F and the other is independently Cl; R.sub.1 is a straight or branched chain (C.sub.3 to C.sub.8) alkyl group substituted by one or two hydroxy moieties, an ether ester (e.g., a polyetherester or phosphate ester) thereof or a pharmaceutically acceptable salt thereof and pharmaceutical compositions thereof useful for treating and/or preventing fungal infections are disclosed.|
|Inventor(s):||Saksena; Anil K. (Upper Montclair, NJ), Girijavallabhan; Viyyoor M. (Parsippany, NJ), Lovey; Raymond G. (West Caldwell, NJ), Pike; Russell E. (Stanhope, NJ), Wang; Haiyan (Dayton, NJ), Liu; Yi-Tsung (Morris Township, NJ), Ganguly; Ashit K. (Upper Montclair, NJ), Bennett; Frank (Piscataway, NJ)|
|Assignee:||Schering Corporation (Kenilworth, NJ)|
|Filing Date:||Jun 02, 1995|
|Claims:||1. A method of making compounds of the formula I ##STR112## wherein X is independently both F or both Cl or one X is independently F and the other is independently Cl, and wherein the absolute stereochemistry at each asterisk carbon (*) is same i.e., S,S or R,R substantially free of S,R or R,S and wherein S or R-lactic acid ester is contacted with pyrrolidine and a hydroxy protecting group reagent converted into the corresponding lactic acid amide, which is selectively reduced to the corresponding propionaldehyde and then converted into the corresponding N-formylaminopropanimine which comprises: |
(a) reacting the N-formylaminopropanimine of the formula II ##STR113## with ethylmagnesium bromide under Grignard reaction conditions sufficient to produce a compound of the formula III ##STR114## wherein the absolute stereochemistry induced at the double asterisk carbon (**) is substantially the same as that at the single asterisk carbon and wherein PG is a hydroxy protecting group and (b) reacting the compound of formula III with a compound of formula IV ##STR115## in the presence of 1,8-diazabicycloundec-7-ene and at elevated temperatures for a time sufficient to produce the compound of formula V ##STR116## and (c) reacting the compound of formula V with a catalytic amount of Pd black on carbon in the presence of formic acid to produce after purification the compounds of formula I.
2. A method of claim 1 wherein S-lactic acid methyl ester is used as the starting material and the Grignard reaction is conducted in the presence of more than one equivalent of bis(trimethylsilyl)acetamide.
3. A method of claim 1 wherein R-lactic acid methyl ester is used as the starting material and the Grignard reaction is conducted in the presence of more than one equivalent of bis(trimethylsilyl)acetamide.
4. The method of claim 1 wherein the compound of formula IV is represented by the formula. ##STR117##
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.